Grantland Hillman

Tamoxifen Metabolite Concentrations, CYP2D6 Genotype, and Breast Cancer Outcomes

Lisa Madlensky, Loki Natarajan, Simone Tchu et al. · Clinical Pharmacology & Therapeutics · 2011 · 329 citations · Full text

Medicine, Oncology, Pharmacology +16

High throughput <scp>HLA</scp> genotyping using 454 sequencing and the Fluidigm Access Array™ system for simplified amplicon library preparation

Priscilla Moonsamy, T. Williams, Persia Bonella et al. · Tissue Antigens · 2013 · 166 citations

Life Sciences, Genetics, Immunology +17

Analytical Performance of a Real-time PCR-based Assay for V600 Mutations in the BRAF Gene, Used as the Companion Diagnostic Test for the Novel BRAF Inhibitor Vemurafenib in Metastatic Melanoma

Harkanwal Halait, Kelli DeMartin, Sweta Shah et al. · Diagnostic Molecular Pathology · 2012 · 145 citations

Medicine, Molecular Biology, Oncology +17

DNA Microarray Technology in the Clinical Environment:<i>The AmpliChip CYP450 Test for CYP2D6 and CYP2C19 Genotyping</i>

José de León, Margaret T. Susce, Maria S. Johnson et al. · CNS Spectrums · 2009 · 88 citations

Medicine, Molecular Genetics, Psychiatry +17

Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy

Alastair M. Thompson, Andrea Johnson, Philip Quinlan et al. · Breast Cancer Research and Treatment · 2010 · 85 citations

Medicine, Oncology, Pharmacology +13